Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Pacific Biosciences of California (PACB)?

Page 1 of 2

To the average investor, there are tons of metrics shareholders can use to analyze Mr. Market. A duo of the best are hedge fund and insider trading interest. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite investment managers can outclass the market by a very impressive margin (see just how much).

Just as necessary, optimistic insider trading sentiment is a second way to analyze the financial markets. There are plenty of reasons for an upper level exec to sell shares of his or her company, but only one, very obvious reason why they would behave bullishly. Several empirical studies have demonstrated the valuable potential of this method if piggybackers know where to look (learn more here).

Pacific Biosciences of California (NASDAQ:PACB)

Now that that’s out of the way, we’re going to analyze the newest info surrounding Pacific Biosciences of California (NASDAQ:PACB).

What does the smart money think about Pacific Biosciences of California (NASDAQ:PACB)?

At the end of the second quarter, a total of 9 of the hedge funds we track held long positions in this stock, a change of 29% from the previous quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their holdings substantially.

When using filings from the hedgies we track, James E. Flynn’s Deerfield Management had the biggest position in Pacific Biosciences of California (NASDAQ:PACB), worth close to $12.4 million, accounting for 0.6% of its total 13F portfolio. On Deerfield Management’s heels is Lee Ainslie of Maverick Capital, with a $8.9 million position; 0.1% of its 13F portfolio is allocated to the stock. Some other hedgies with similar optimism include Jeremy Green’s Redmile Group, Jacob Gottlieb’s Visium Asset Management and Israel Englander’s Millennium Management.

As industrywide interest increased, particular hedge funds have jumped into Pacific Biosciences of California (NASDAQ:PACB) headfirst. Deerfield Management, managed by James E. Flynn, established the largest position in Pacific Biosciences of California (NASDAQ:PACB). Deerfield Management had 12.4 million invested in the company at the end of the quarter. Lee Ainslie’s Maverick Capital also initiated a $8.9 million position during the quarter. The following funds were also among the new PACB investors: Jeremy Green’s Redmile Group, Jacob Gottlieb’s Visium Asset Management, and Israel Englander’s Millennium Management.

Insider trading activity in Pacific Biosciences of California (NASDAQ:PACB)

Insider buying made by high-level executives is at its handiest when the company we’re looking at has seen transactions within the past half-year. Over the last six-month time period, Pacific Biosciences of California (NASDAQ:PACB) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

We’ll also review the relationship between both of these indicators in other stocks similar to Pacific Biosciences of California (NASDAQ:PACB). These stocks are ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Geron Corporation (NASDAQ:GERN), ImmunoCellular Therapeutics Ltd (NYSEAMEX:IMUC), and Targacept , Inc. (NASDAQ:TRGT). This group of stocks belong to the biotechnology industry and their market caps resemble PACB’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!